BCHE and Alzheimer disease: Currently approved drugs for the symptomatic treatment of AD comprise cholinesterase inhibitors and N-methyl-D-aspartic acid (NMDA) receptor antagonists [66], both of which provide at best relatively short symptomatic relief; moreover, their efficacy significantly drops as the disease progresses [67].